<?xml version="1.0" encoding="UTF-8"?><!--Transformation version 1.3--><legislativeDoc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://www.lexisnexis.com/xmlschemas/content/public/legislativedoc/1/" schemaVersion="1.0"><legislativeDocHead><citations><citeForThisResource citeDefinition="#7159#349#000059#     1#          535#">Va. Code Ann. § 59.1-535</citeForThisResource></citations><legislativeBodyInfo><jurisdiction><jurisSystem normalizedLongName="Virginia" normalizedShortName="VA"/></jurisdiction></legislativeBodyInfo></legislativeDocHead><legislativeDocBody><statute><level levelType="section"><anchor id="_59.1-535"/><heading><desig>§ 59.1-535.</desig><title>Prohibitions</title></heading><level levelType="paragraph"><bodyText><p>During any influenza vaccine shortage period, it shall be unlawful for any person to sell or administer, or to offer to sell or administer, influenza vaccine at an unconscionable price within the Commonwealth. Actual sales at the increased price shall not be required for the increase to be considered unconscionable. In determining whether the price at which influenza vaccine is sold or administered is unconscionable, the following shall be considered:</p></bodyText><level levelType="paragraph"><anchor id="_1"/><heading><desig>1.</desig></heading><bodyText><p> Whether the price charged by the person for selling or administering the influenza vaccine grossly exceeded the price charged by the person therefor during the 10 days immediately prior to the commencement of the influenza vaccine shortage period; however, with respect to any person who was offering influenza vaccine at a reduced price immediately prior to the commencement of the influenza vaccine shortage period, the price at which the person usually offers influenza vaccine shall be used as the benchmark for these purposes;</p></bodyText></level><level levelType="paragraph"><anchor id="_2"/><heading><desig>2.</desig></heading><bodyText><p> Whether the price charged by the person grossly exceeded the price at which influenza vaccine was readily obtainable by consumers in the trade area during the 10 days immediately prior to the commencement of the influenza vaccine shortage period; and</p></bodyText></level><level levelType="paragraph"><anchor id="_3"/><heading><desig>3.</desig></heading><bodyText><p> Whether the increase in the amount charged by the person was attributable solely to additional costs incurred by the person in connection with the sale of the influenza vaccine, including additional costs imposed by the person's source. Proof that the person incurred such additional costs during the time of the influenza vaccine shortage period shall be prima facie evidence that the price increase was not unconscionable.</p></bodyText></level></level><history><historyGroup groupType="history-citation"><historyItem><bodyText><p><citation normalizedCite="2005 VA CH 861"><content><span normalizedCite="2005 Va. Ch. 861">2005, c. 861<locator><locatorKey><keyName name="citeReference"/><keyValue value="#1834#131#2005#000861#"/></locatorKey></locator></span></content></citation>.</p></bodyText></historyItem></historyGroup></history></level></statute></legislativeDocBody><metadata><dc:metadata xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:identifier identifierScheme="PGUID">urn:contentItem:5K0Y-PVF0-004G-K4M2-00000-00</dc:identifier><dc:source sourceScheme="productContentSetIdentifier">10816</dc:source><dc:date dateType="last-updated">2016-06-15</dc:date></dc:metadata><publicationInfo><publicationName>CODE OF VIRGINIA </publicationName><copyright>Copyright © 2016  by Matthew Bender &amp; Company, Inc. a member of the LexisNexis Group. All rights reserved</copyright></publicationInfo><hierarchy><hierarchyLevel levelType="title"><heading><desig>TITLE 59.1.</desig><title>TRADE AND COMMERCE</title></heading><hierarchyLevel levelType="chapter"><heading><desig>CHAPTER 48.</desig><title>INFLUENZA VACCINE PRICE GOUGING</title></heading></hierarchyLevel></hierarchyLevel></hierarchy><classificationGroup classificationScheme="indexing-terms"><classification classificationScheme="legal"><classificationItem><className>Business &amp; Corporate Compliance</className><classCode>Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI7cGFyZW50Z3VpZD0</classCode><classificationItem score="90"><className>Antitrust</className><classCode>Z3VpZD11cm46dG9waWM6REEyRTNDM0JGQzYyNEMyOEFGNTAwNUJEOUU1MDg4NjU7cGFyZW50Z3VpZD11cm46dG9waWM6MUFEMUQ2QTA1OUZCNEE5RjkzNTA2RERFMUNEOTk1RTI</classCode></classificationItem></classificationItem><classificationItem><className>Contracts Law</className><classCode>Z3VpZD11cm46dG9waWM6QzY0RTZFMzE0RjkwNDdFQUI5M0U5N0ZFMjYyREMyQzU7cGFyZW50Z3VpZD0</classCode><classificationItem score="52"><className>General Overview</className><classCode>Z3VpZD11cm46dG9waWM6RjA2M0NFN0NBODg4NEYzNzhDM0U0NkY0QUYyREU0OUU7cGFyZW50Z3VpZD11cm46dG9waWM6REI5NzAxRTFEOUY3NEUzQ0FFQTQxMDg4RDVEREM1ODI</classCode></classificationItem></classificationItem></classification></classificationGroup></metadata></legislativeDoc>